CGRP Archives -

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the

Chasing rivals, AbbVie files migraine prevention drug atogepant in EU

https://pharmaphorum.com/news/chasing-rivals-abbvie-files-migraine-prevention-drug-atogepant-in-eu/

News/ News/ Sales and Marketing

Pfizer upgrades Biohaven alliance to a takeover bid

Phil Taylor Biohaven Pharmaceuticals, CGRP, M&A, migraine, Pfizer 0 Comment

Not content with a $1.2 billion licensing deal for Biohaven Pharma’s oral migraine therapy rimegepant, Pfizer has just

Pfizer upgrades Biohaven alliance to a takeover bid

https://pharmaphorum.com/news/pfizer-upgrades-biohaven-alliance-to-a-takeover-bid/

Market Access/ News/ News/ News/ Sales and Marketing

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Phil Taylor AbbVie, Biohaven Pharmaceuticals, CGRP, migraine, Pfizer, Qulipta, Vydura 0 Comment

Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff

Pfizer/Biohaven migraine drug rimegepant gets EU green light

https://pharmaphorum.com/news/pfizer-biohaven-migraine-drug-rimegepant-gets-eu-green-light/

News/ News/ R&D

Amid crowded migraine market, Lundbeck goes its own way

Phil Taylor CGRP, Lundbeck, migraine, PACAP, Vyepti 0 Comment

The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting

Amid crowded migraine market, Lundbeck goes its own way

https://pharmaphorum.com/news/amid-crowded-migraine-market-lundbeck-goes-its-own-way/

News/ News/ Sales and Marketing

Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug

Phil Taylor Biohaven Pharmaceuticals, central nervous system, CGRP, migraine, partnering, Pfizer 0 Comment

Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights

Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug

https://pharmaphorum.com/news/pfizer-strikes-1-2bn-licensing-deal-for-biohaven-migraine-drug/

Market Access/ News/ News

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

Phil Taylor AbbVie, Biohaven Pharmaceuticals, CGRP, migraine, prevention, Qulipta 0 Comment

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

https://pharmaphorum.com/news/abbvies-qulipta-cleared-for-migraine-prevention-setting-up-biohaven-clash/

News/ News/ R&D/ Top stories

Novartis’ Aimovig tops topiramate in migraine face-off

Phil Taylor Aimovig, Amgen, CGRP, migraine, neurology, Novartis, prevention 0 Comment

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to

Novartis’ Aimovig tops topiramate in migraine face-off

https://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/

Market Access/ News/ News

After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovy

Phil Taylor CGRP, migraine, NICE, Teva 0 Comment

Several months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed

After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovy

https://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/

Market Access/ News/ News

CHMP turns down Lilly’s Emgality for cluster headache

Phil Taylor CGRP, chronic migraine, cluster headache, Eli Lilly, Emgality 0 Comment

An EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic

CHMP turns down Lilly’s Emgality for cluster headache

https://pharmaphorum.com/news/chmp-turns-down-lillys-emgality-for-cluster-headache/

Trending

CGRP

Login